Information Provided By: 
Fly News Breaks for June 20, 2016
SRPT
Jun 20, 2016 | 07:57 EDT
Oppenheimer analyst Christopher Mara says Sarepta has entered a quiet period, indicating that analysis/submission of dystrophin data from 48-week biopsies of 13 PROMOVI patients to the FDA is "imminent." The analyst believes the company will submit the data by June 30. Furthermore, Mara anticipates Sarepta's Eteplirsen accelerated approval as he believes PROMOVI biopsy data will confirm increases of dystrophin on the order of about 0.9% versus baseline. The analyst reiterates an Outperform rating and $60 price target on the shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
